Loading patent…
AssigneeAstellas Pharma Inc.
InventorsHiroyuki Umejima, Ippei Kurimoto, Atsushi Kanbayashi, Chieko Mori
Estimating the term…
Provided is a preparation of ramosetron which is stable under irradiation with light. The solid pharmaceutical composition of the present invention can provide a stable preparation by blending a compound absorbing light having a specific wavelength with ramosetron which is unstable, usually under irradiation with light, or a pharmaceutically acceptable salt thereof. Particularly, this technique is useful because it is adaptable to a preparation containing ramosetron or a pharmaceutically acceptable salt thereof at a low content or an orally disintegrating tablet containing ramosetron or a pharmaceutically acceptable salt thereof. Also, the present invention relates to a method for stabilizing a solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof, which is characterized by blending a compound having characteristics of absorbing light having a specific wavelength.
A solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof, which comprises one or two or more kinds of the compounds selected from the group consisting of the compounds having 4.5 or more of the area under the spectrum curve at the wavelength range of 220 nm to 240 nm and/or 2.5 or more of the area under the spectrum curve at the wavelength range of 280 nm to 300 nm in a 0.001 w/v % aqueous solution thereof.
A particulate pharmaceutical composition, wherein ramosetron or a pharmaceutically acceptable salt thereof is coated with one, or two or more kinds of the compounds selected from the group consisting of the compounds having 4.5 or more of the area under the spectrum curve at the wavelength range of 220 nm to 240 nm and/or 2.5 or more of the area under the spectrum curve at the wavelength range of 280 nm to 300 nm.
A method for stabilizing a solid pharmaceutical composition of ramosetron or a pharmaceutically acceptable salt thereof, which comprises blending one or two or more kinds of the compounds selected from the group consisting of the compounds having 4.5 or more of the area under the spectrum curve at the wavelength range of 220 nm to 240 nm and/or 2.5 or more of the area under the spectrum curve at the wavelength range of 280 nm to 300 nm in a 0.001 w/v % aqueous solution thereof.
Dependencies are inferred from the claim text.